Tagged with BI

Canada Looking back on his first year as CEO of Organigram, Greg Engel proudly highlights the successful transition of the company from being a low-cost to a high-quality cannabis producer with premium products. He emphasizes Organigram’s close collaboration with both federal and provincial governments, on both the medical and recreational business,…

Canada Hydropothecary is the leading medicinal cannabis producer in Quebec, founded in 2013 by two brothers-in-law, Sebastien St-Louis and Adam Miron. Terry Lake, former Minister of Health for British Colombia, discusses his new role as Vice President Corporate Social Responsibility, the stigma surrounding the cannabis plant and how to bring innovative…

Canada Upon opening an R&D center in Mississauga in 2017, Biolab Pharma Canada, headed by Paulo Wickbold Marques, became the first Brazilian pharmaceutical company to establish an affiliate in Canada. In this interview, Paulo describes Biolab’s bold leap from Latin America, the strengths of the Canadian pharmaceutical landscape and how the…

Canada Introducing Vantage BioTrials, a CRO focused on operational excellence with a lean and holistic approach to each project, Vatché Bartekian, president and co-founder, also advocates for greater visibility for Canada on the international stage and an increase in collaboration within the pharmaceutical industry and regulatory bodies. Vantage BioTrials celebrated its…

Serbia Serbia macroeconomic factsheet including data on population, GDP, education and life expectancy. Serbia has risen 50 places in the World Bank’s ‘Doing Business’ rankings from 93rd in 2014 to 43rd in 2018. Serbia’s GDP per capita between 2008 and 2016. International comparison of healthcare spending growth and GDP growth between…

Serbia In a market environment that, up until recently, has been severely difficult for producers of chemical pharmaceutical products to operate in, three enterprising Serbian companies – Pharmanova, INNventa and Esensa – have found success by stepping up their offering in dietary and other health supplements, as well as cosmetics and…

Poland Maciej Wieczorek, president of Celon Pharma, discusses the award-winning success of the 2016 IPO on the Warsaw stock exchange and the opportunities this has opened up, as well as investment strategy to assure the company’s impressive growth. Furthermore, he surveys the Polish R&D landscape and discusses the importance of a…

India For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India country president Jawed Zia points out that “India, in terms of demographics, is the youngest nation in the world. The…

Serbia Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared with 44 in Bulgaria and 27 in Croatia; meaning a severe lack of patient access to much-needed treatments as well as an extremely challenging environment for innovative…

Serbia Nebojsa Skuljec has held various positions in MSD Healthcare across the Balkans before his promotion to country lead for Serbia and Balkans emerging markets 14 months ago. In this interview Skuljec tells the story of MSD’s journey from humble origins to one of the big pharma players in Serbia, growth…

Serbia Branislav Kotlarik, Ferring’s general manager for the Balkans – whose remit includes Hungary, Romania and Bulgaria as well as all of ex-Yugoslavia – gives his insights into managing such a diverse region; Ferring’s commitment to reproductive medicine; and the intricacies of gaining reimbursement for innovative products on the Serbian market.…

Brazil Maria del Pilar Muñoz, vice-president in charge of M&A and Sustainability at Eurofarma, one of the largest and most innovative pharmaceutical companies in Brazil with operations in 20 countries across Latin Americ , provides insights into the key competitive advantages of Eurofarma, its unique internationalization strategy, and the company’s historical…